Three studies point to effectiveness of new therapies for multiple myelomaDecember 08, 2015
ORLANDO, FL -- In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana-Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment-resistant forms of the disease.
The trials pair the oral drugs lenalidomide and dexamethasone with other agents, each of which exploits a different vulnerability in tumor cells. The various combinations are at different stages of clinical testing, but all are proving effective at producing at least partial remissions and increasing the duration of those remissions, with tolerable side effects for most patients.
"With the recent approvals of daratumumab, ixazomib, and now elotuzumab, we have seen an unprecedented pace of progress in myeloma therapy this year. The results from these studies reflect the real benefits our patients can anticipate from these very important advances in currently available treatment," said Paul Richardson, clinical program leader and director of clinical research at Dana-Farber's Jerome Lipper Multiple Myeloma Center.
All of the patients in the three trials had myeloma that had either relapsed or become resistant to other therapies. Patients received a tandem of lenalidomide, a drug that kills tumor cells, blocks blood vessel growth, and acts on the immune system, and dexamethasone, an anti-inflammatory agent, plus one of three new agents:
A combined phase 1 and phase 2 trial of lenalidomide/dexamethasone plus a breakthrough antibody therapy called daratumumab (Darzalexâ„¢). Of 32 patients participating in the trial, 11 had a partial response to the drug regimen, meaning a decrease in the extent of the cancer, and 53 had a very good partial response, meaning the level of certain myeloma-related proteins in the blood declines by more than 90 percent. In 93 percent of cases, remissions lasted for the entire 12 months that the patients have been tracked so far. The most common adverse side effects were neutropenia (a shortage of certain white blood cells), muscle spasms, cough, diarrhea, fatigue, and hypertension.
Abstract # 507 embargoed until presented Monday, December 7, at 7:30 a.m. ET, in Hall E1, Level 2, Orange County Convention Center
A phase 3 trial of lenalidomide/dexamethasone plus ixazomib (NinlaroÂ®), a 'proteasome inhibitor' that blocks the ability of cancer cells to reuse certain proteins. The U.S. Food and Drug Administration approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therapy. In the trial, patients receiving all three drugs had a 35 percent improvement in progression-free survival -- the length of time before the disease begins to worsen -- compared to those receiving lenalidomide and dexamethasone alone. The adverse side effects were similar in intensity and prevalence to those associated with lenalidome and dexamethasone.
Abstract # 727 embargoed until presented Monday, December 7, at 2:45 p.m. ET, in Tangerine 2 (WF2), Level 2 of the Orange County Convention Center
A phase 3 trial of lenalidomide/dexamethasone with elotuzumab (Emplicitiâ„¢), an antibody therapy that attacks myeloma cells directly and spurs the immune system to launch an attack of its own. Treatment with the three-drug regimen resulted in a 30 percent reduction in the risk that the disease would progress over a three-year period, compared to a course of lenalidomide and dexamethasone alone. Overall, 79 percent of the 321 patients who received the three-drug regimen responded to it, compared to 66 percent of the 325 patients in the two-drug group. The most common adverse side effects were lymphopenia (a condition of abnormally low levels of white blood cells called lymphocytes), neutropenia, blood platelet deficiency, and infection.
Abstract #28 embargoed until presented Saturday, December 5, at 8:15 AM, on Tangerine 2 (WF2), Level 2 of the Orange County Convention Center
"In summary, these encouraging data build upon the real success of our translational efforts in myeloma over the last decade, and provide exciting new options with the real promise of improving patient outcome," said Richardson, who is also the R.J. Corman professor at Harvard Medical School.
For a full list of co-authors and their affiliated institutions for each of the abstracts, please visit http://www.hematology.org/Annual-Meeting/Abstracts/.
About Dana-Farber Cancer Institute
From achieving the first remissions in cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report's Best Hospitals for both adult and pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber/Brigham and Women's Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston's Longwood Medical Area.
Dana-Farber is dedicated to a unique 50/50 balance between cancer research and care, and much of the Institute's work is dedicated to translating the results of its discovery into new treatments for patients in Boston, and around the world.
Dana-Farber Cancer Institute
Related Dexamethasone Current Events and Dexamethasone News Articles
Nanoscale Trojan horses treat inflammation
Nanosized Trojan horses created from a patient's own immune cells have successfully treated inflammation by overcoming the body's complex defense mechanisms, perhaps leading to broader applications for treating diseases characterized by inflammation, such as cancer and cardiovascular diseases.
Updated Cochrane Review: Corticosteroids for managing tuberculous meningitis
The Cochrane Infectious Diseases Group (CIDG) have carried out a review update to evaluate the effects of corticosteroids being used alongside anti-tuberculosis medication to treat people suffering from tuberculous meningitis.
Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.
Netupitant/palonosetron for prevention of nausea and vomiting: Added benefit not proven
The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug combination netupitant/palonosetron (trade name: Akynzeo) offers an added benefit over the appropriate comparator therapy (ACT).
D&R: A new adipogenic cocktail that produces functional adipocytes from MSCs
Adipocyte dysfunction is directly associated with pathologies characterized by metabolic disorders including obesity, diabetes mellitus type II and metabolic syndrome. Adipogenesis is a complex process that has been extensively studied in different cell models.
Studies suggest new ways to inhibit oncogenes, enhance tumor-suppressor activity
Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes. The findings were reported in the journals Nature Communications and Nature Genetics.
Nanowire implants offer remote-controlled drug delivery
A team of researchers has created a new implantable drug-delivery system using nanowires that can be wirelessly controlled.
Stress hormones could undermine breast cancer therapy
Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy.
Some common anti-nausea medications used post-operatively could increase patients' arrhythmia risk
Certain commonly prescribed anti-nausea medications given to patients during or after an operation could increase their risk of developing an irregular heartbeat, new research has found.
Discovery could help reverse glucocorticoid resistance in some young leukemia patients
Researchers led by St. Jude Children's Research Hospital scientists have identified a mechanism that helps leukemia cells resist glucocorticoids, a finding that lays the foundation for more effective treatment of cancer and possibly a host of autoimmune diseases.
More Dexamethasone Current Events and Dexamethasone News Articles